TerminatedPhase 2/3

Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF

Stopped: Due to inter-city travel restrictions for COVID-19, regular follow-up for most patients is not possible

China5 participantsStarted 2019-10-12

Plain-language summary

As a primary exploratory study, this study aims to evaluate the short-term effectiveness of intravitreal Conbercept injection in UME, and to explore the correlation between inflammatory factors like VEGF and the responsiveness to treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * age \>= 18 years old * competent in signing the informed consent * no severe systemic diseases unrelated to uveitis * fulfill the criteria of refractory UME Exclusion Criteria: * pregnant or preparing pregnancy * already in other clinical trials * blood pressure \>= 180/110mmHg * BCVA of the contralateral eye \<= 20/200 * cardiovascular events within 3 months

What they're measuring

Changes of best corrected visual acuity (BCVA)

Timeframe: baseline and at 1, 2, 3, 4, 5, 6 months after injection

Changes of central retinal thickness (CRT)

Timeframe: baseline and at 1, 2, 3, 4, 5, 6 months after injection

Trial details

NCT IDNCT04296838

SponsorPeking Union Medical College Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-04-12

View on ClinicalTrials.gov More Uveitis trials